Video

Jason R. Gotlib Discusses MPN Research at Stanford

Author(s):

Jason R. Gotlib

Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Jason R. Gotlib, Associate Professor of Medicine (Hematology) at the Stanford University Medical Center, discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Recognized for advancing the science of MPNs, Dr. Gotlib is the Principal Investigator for a number of clinical trials in the classic MPNs, and for a database registry specifically for MPN research. In addition, he is acclaimed for his leadership in professional and patient education conferences. Besides mentoring medical fellows and serving as the Editor-in-Chief of The Hematologist, Gotlib is highly regarded by his patients for his dedication and sincerity

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content
Image of doctor
June 21st 2025

What Patients With Polycythemia Vera Should Know After ASCO 2025

Dr. Joshua K. Sabari Dr. Raajit K. Rampal
Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of blood cells.
June 11th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
blood cells.
May 29th 2025

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

Ryan Scott
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
Image of blood cells.
May 21st 2025

Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs

Ryan Scott
JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.